Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Molecular dynamics simulations reveal fundamental role of water as factor determining affinity of binding of beta-blocker nebivolol to beta(2)-adrenergic receptor.

Kaszuba K, Róg T, Bryl K, Vattulainen I, Karttunen M.

J Phys Chem B. 2010 Jul 1;114(25):8374-86. doi: 10.1021/jp909971f.

PMID:
20524635
2.

Stereochemical comparison of nebivolol with other beta-blockers.

Siebert CD, Hänsicke A, Nagel T.

Chirality. 2008 Feb;20(2):103-9. Review.

PMID:
18072266
3.

The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers.

Pauwels PJ, Gommeren W, Van Lommen G, Janssen PA, Leysen JE.

Mol Pharmacol. 1988 Dec;34(6):843-51.

PMID:
2462161
4.

Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.

Prisant LM.

J Clin Pharmacol. 2008 Feb;48(2):225-39. Epub 2007 Dec 14. Review.

PMID:
18083889
5.

Nebivolol: the somewhat-different beta-adrenergic receptor blocker.

Münzel T, Gori T.

J Am Coll Cardiol. 2009 Oct 13;54(16):1491-9. doi: 10.1016/j.jacc.2009.05.066. Review.

8.

Beta-adrenoceptor-mediated cAMP accumulation in cardiac cells: effects of nebivolol.

Pauwels PJ, Leysen JE, Janssen PA.

Eur J Pharmacol. 1989 Dec 5;172(6):471-9.

PMID:
2575531
9.

The role of the new beta-blockers in treating cardiovascular disease.

Weber MA.

Am J Hypertens. 2005 Dec;18(12 Pt 2):169S-176S. Review.

PMID:
16373195
10.

A comparison of the beta1-selectivity of three beta1-selective beta-blockers.

Nuttall SL, Routledge HC, Kendall MJ.

J Clin Pharm Ther. 2003 Jun;28(3):179-86.

PMID:
12795776
11.

Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.

Ignarro LJ.

Cardiovasc Ther. 2008 Summer;26(2):115-34. doi: 10.1111/j.1527-3466.2008.00044.x.

PMID:
18485134
12.

Nebivolol: a third-generation beta-adrenergic blocker.

Veverka A, Nuzum DS, Jolly JL.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1353-60. Epub 2006 Jul 5. Review.

PMID:
16822893
13.

Nitric oxide mechanisms of nebivolol.

Maffei A, Lembo G.

Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27. doi: 10.1177/1753944709104496. Epub 2009 May 14. Review.

PMID:
19443516
14.

Potent and selective human beta(3)-adrenergic receptor antagonists.

Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, Cascieri MA, Weber AE.

J Pharmacol Exp Ther. 1999 Aug;290(2):649-55.

15.

The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists.

Macchia B, Balsamo A, Breschi MC, Chiellini G, Macchia M, Martinelli A, Martini C, Nardini C, Nencetti S, Rossello A, et al.

J Med Chem. 1994 May 13;37(10):1518-25.

PMID:
7910217
16.

Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.

Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C.

J Am Coll Cardiol. 2009 Apr 28;53(17):1532-8. doi: 10.1016/j.jacc.2008.11.057.

17.

Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.

Huber T, Menon S, Sakmar TP.

Biochemistry. 2008 Oct 21;47(42):11013-23. doi: 10.1021/bi800891r. Epub 2008 Sep 27.

PMID:
18821775
18.

Nebivolol: new therapy update.

Sule SS, Frishman W.

Cardiol Rev. 2006 Sep-Oct;14(5):259-64. Review.

PMID:
16924166
19.
20.

Cardiovascular effects of intracerebroventricular injections of (+/-)-nebivolol and its enantiomers--a comparison with those of metoprolol in the rat.

Midol-Monnet M, Davy M, Heimburger M, Beslot F, Cohen Y.

J Pharm Pharmacol. 1991 Jul;43(7):504-9.

PMID:
1682465

Supplemental Content

Support Center